Alira Health Acquires Sourcia

Alira Health has acquired full-service contract research organization (CRO) Sourcia. The deal’s terms were not disclosed by either company. 

Sourcia provides services for Phase I to Phase IV clinical trials with a focus on biotech, medical devices, and digital therapeutics. Founded in 2012, Sourcia is based in Europe, with headquarters in Zevenbergen, The Netherlands, and operational offices in Munich, Germany; and Vienna, Austria.
 
“The increasing need for time-efficient and cost-effective drug development is driving demand for CRO services. We believe that Sourcia’s integrated outsourcing model is particularly suited to the needs of today’s market,” said Benjamin Chambon, chief commercial officer of Alira Health. “Sourcia is a well-established player in the European CRO market with an experienced leadership team and a strong reputation in the VC community for a pattern of innovation. We are incredibly honored to welcome them to Alira Health.”
 
“Sourcia’s unique integrated outsourcing model lets biotech and medtech clients manage clinical trials with the highest level of effectiveness, efficiency, and trust”, said Verena Koepke, managing partner of Sourcia. “We are pleased to become part of Alira Health and expand our capabilities of full-service clinical work. Alira Health’s broad range of tech-enabled consulting and advisory services, complemented by its mission to humanize healthcare, is where our industry is headed.”
 
Founded in 2012, Sourcia is a CRO that provides clinical trial services for Phase I to Phase IV / Pre- and Post CE marking-related clinical trials. Sourcia targets small-to-medium-sized biotech and medical device companies located in Europe. 
 
Alira Health is an international patient-centric and technology-enabled advisory firm that works with healthcare and life sciences organizations looking for support across their solutions lifecycle. From development to medical care, the company provides a full spectrum of services including research and clinical development solutions, technology-powered consulting, and real-world evidence. Its integrated and multidisciplinary team of more than 500 scientists, strategists, economists, clinicians, and biostatisticians collaborates across North America, Europe, and Asia, and advises 80 percent of the top 50 percent of medtech companies and 75 percent of the top 50 percent of pharmaceutical firms.